MedTrace Logo

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer

NCT07483307 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2026-03-19

No results posted yet for this study

Summary

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).

Conditions

Interventions

DRUG

Neoadjuvant endocrine therapy

The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.

Sponsors & Collaborators

Principal Investigators

  • Anita SKCCSC(P Mamtani, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-13
Primary Completion
2030-03-13
Completion
2030-03-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07483307 on ClinicalTrials.gov